Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 2.73B 2.37B 2.22B 2.03B 3.82B 259B 3.88B 25.92B 10.17B 130B 10.24B 10.02B 432B P/E 2026 *
-147x
P/E 2027 * 39.9x
Enterprise Value 2.73B 2.37B 2.22B 2.03B 3.82B 259B 3.88B 25.92B 10.17B 130B 10.24B 10.02B 432B EV / Sales 2026 *
3.09x
EV / Sales 2027 * 1.99x
Free-Float
95.54%
Yield 2026 *
-
Yield 2027 * -
1 day-0.32%
1 week+0.41%
Current month+4.77%
1 month-2.68%
3 months-4.94%
6 months-5.29%
Current year-5.92%
1 week 42.62
Extreme 42.625
52.5
1 month 42.62
Extreme 42.625
52.5
Current year 42.45
Extreme 42.45
59.68
1 year 40.26
Extreme 40.26
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 21/12/2005
Director of Finance/CFO 67 22/08/2021
Compliance Officer 63 31/12/2011
Director TitleAgeSince
Director/Board Member 64 21/12/2005
Chairman 81 09/08/2016
Director/Board Member 80 15/11/2010
Date Insider Type Main position Quantity % Market Cap.
29/07/26 Free

Chief Financial Officer

1,250 0.0022%
29/07/26 Free

Founder

29,849 0.0532%
29/07/26 Free

Chief Technology Officer

750 0.0013%
Change 5-day change 1-year change 3-year change Capi.($)
-0.32%+0.41%+24.59%+45.31% 2.73B
+0.03%-1.53%+58.89%+22.26% 317B
+0.10%+0.03%+34.52%-10.18% 72.79B
+2.60%+2.98%+41.03%+102.22% 9.91B
+2.42%-6.99%-2.16%-3.95% 8.16B
+1.83%+10.45%-25.04%-13.29% 4.51B
+3.60%+10.67%-32.29%+11.14% 3.94B
+3.02%+5.81%-14.51%+24.85% 3.71B
-3.27%-3.63%-5.69%-6.49% 2.24B
-0.91%-1.13%-26.64%+28.31% 1.79B
Average +0.91%+0.72%+5.27%+20.02% 42.67B
Weighted average by Cap. +0.20%-1.17%+49.87%+17.65%

Financials

2026 *2027 *
Net sales 881M 765M 716M 655M 1.24B 83.82B 1.25B 8.38B 3.29B 41.97B 3.31B 3.24B 140B 1.37B 1.19B 1.11B 1.02B 1.92B 130B 1.95B 13.02B 5.11B 65.25B 5.14B 5.03B 217B
Net income -18.67M -16.2M -15.17M -13.88M -26.16M -1.78B -26.55M -177M -69.64M -889M -70.08M -68.56M -2.96B 68.56M 59.51M 55.71M 50.97M 96.09M 6.52B 97.52M 652M 256M 3.27B 257M 252M 10.87B
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
06/08/26 US$46.76 -0.32% 1,342,231
05/08/26 US$46.91 +8.46% 1,671,843
04/08/26 US$43.25 -5.98% 3,705,542
03/08/26 US$46.00 +3.07% 4,518,516
31/07/26 US$44.63 -2.15% 573,626
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
46.91USD
Average target price
62.50USD
Spread / Average Target
+33.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock